AGM/EGM Notice
Lupin Publishes Postal Ballot Notice
Lupin Ltd published newspaper advertisements informing shareholders about its Postal Ballot Notice and remote e-voting details.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.



Bearish
3
Neutral
5
Bullish
6
Bearish
34
Neutral
5
Bullish
7
Bearish
31
Neutral
0
Bullish
1

Pharmaceuticals & Biotechnology
Pharmaceuticals
89,858 Cr
Low Risk
17.2
39.0
0.1
3.7
2,530.00
1,893.25
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Lupin Ltd (LUPIN) is currently trading at 1,965.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Lupin is an innovation-led multinational pharmaceutical company developing and marketing branded and generic formulations, biotechnology products, biosimilars, specialty medicines, and active pharmaceutical ingredients across India, the United States, Europe, Canada, Australia, and emerging markets. Its established strengths span cardiovascular, diabetes, respiratory, anti-tuberculosis, cephalosporin, injectables, ophthalmology, and other chronic-care therapies. Lupin delivered Q2 FY27 operating revenue of INR 7,827 crore, up 11% year on year, despite sharp U.S. competitive pressure on Tolvaptan and loss of exclusivity for selected products. India grew 14.7%, while Other Developed Markets expanded 46%, demonstrating that business diversification is increasingly cushioning volatility in the U.S. generic portfolio. The strategic pivot is toward more durable, complex products: Lupin plans over 60 U.S. launches across three years, including approximately 25 injectable and respiratory products, five biosimilars, and several 505(b)(2) products. This pipeline is intended to replace dependence on one-off generic exclusivities with specialty, respiratory, injectable, and biologic opportunities. India is becoming a stronger structural growth anchor. Chronic therapies represented approximately 66% of the portfolio in the first half, diabetes grew above 25% in the quarter, and management aims to raise chronic contribution toward 70% over five years, supported by nearly 11,400 representatives and more than 80 planned product launches. Near-term earnings quality faces pressure even as the long-term opportunity improves. Q2 EBITDA margin fell to 25.1% from 31.3% a year earlier because of U.S. pricing pressure, higher personnel and manufacturing costs, settlement expenses, and elevated investment in R&D, biosimilars, specialty commercialization, technology, and market-access capabilities.
Over the past 52 weeks, Lupin Ltd has traded between a low of ₹1,893.25 and a high of ₹2,530.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Lupin Ltd has a market capitalization of approximately 89,350.48. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Lupin Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.11 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 89,350.48 Cr, Lupin Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Lupin Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Lupin Ltd is 17.11. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Lupin reported a 25.1% EBITDA margin in Q2 FY27, down from 31.3% in Q2 FY26. Employee-benefit expenses rose 29% to Rs 1,424 crore and manufacturing and other expenses increased 23% to Rs 2,438 crore, while competition reduced contribution from Tolvaptan.
Lupin reported US sales of USD 317 million in Q2 FY2027, down 13.4% quarter on quarter on a constant-currency basis. Management said increased competition and loss of exclusivity in selected products drove the decline. It later clarified that Tolvaptan was the main pressure point, while Mirabegron remained relatively stable.
Lupin's India business grew 14.7% year on year in Q2 FY27. Domestic revenue was reported at ₹2,383.6 crore, compared with ₹2,077.7 crore in the year-earlier quarter.
Lupin recorded a ₹5.91 crore standalone loss after booking a ₹76.93 crore impairment against an investment in a subsidiary. The company had ₹81.12 crore of profit before exceptional items and tax, but the impairment and ₹10.10 crore tax expense reduced the final result.
AGM/EGM Notice
Lupin Ltd published newspaper advertisements informing shareholders about its Postal Ballot Notice and remote e-voting details.
AGM/EGM Notice
Lupin has issued a postal ballot notice seeking shareholder approval for Akhil Gupta’s appointment as an Independent Director for a five-year term.
Product/Operations Update
Lupin announced the European launch of Ranluspec, its biosimilar ranibizumab, through partner Sandoz across Europe excluding Germany.